Kodiak Sciences Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Net Loss Per Common Share
- Net Loss per Common Share
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Numerator: | |||
| Net loss | $(229,967) | $(176,207) | $(260,491) |
| Denominator: | |||
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 53,208,311 | 52,583,148 | 52,414,256 |
| Net loss per share, basic and diluted | $(4.32) | $(3.35) | $(4.97) |
The following common share equivalents were excluded from the computation of diluted net loss per common share for the periods presented because their inclusion would have been antidilutive:
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Outstanding stock options | 22,223,236 | 19,873,073 | 17,601,466 |
| Unvested restricted shares | 120,820 | 121,660 | 164,817 |
| ESPP | 38,203 | 44,547 | 70,761 |
| Total | 22,382,259 | 20,039,280 | 17,837,044 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.